Imbalanced cross-overs [Study Per­for­mance]

posted by Helmut Homepage – Vienna, Austria, 2014-06-06 16:47 (4405 d 19:47 ago) – Posting: # 13038
Views: 22,690

Hi Khaoula,

❝ […] we collected the results of 15 subjects and we analyzed Kinetica without protocol for the management of dropouts


[image]We recently have submitted a paper to the AAPS J (which currently is under review). It seems that Kinetica is not able to correctly deal with imbalanced studies. I strongly suggest to use another soft­ware (we got correct results in R, Phoenix/WinNonlin, EquivTest/PK, and SAS).

❝ we had abberants results: for Cmax CV = 0,03 % for hight variable drug …


I don’t understand what you mean here. The limit for HVDs/HVDPs is 30% CV of the reference obtained in a replicate design. CVintra from a 2×2 serves only as a hint of a highly variable reference (since pooled from CVWR and CVWT).

❝ power: 50% …


A posteriori (aka post-hoc) power is irrelevant in BE. Stop calculating it.
Either the study passes, or not.

❝ with subject effect and subject/sequence effect


Subject effects are normal in a cross-over. It tells you that subjects differ – well, they should…

❝ […] the exclusion of subject N 15 have impact in the result of the study?


If evaluated by Kinetica, yes. :-(

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
279 visitors (0 registered, 279 guests [including 17 identified bots]).
Forum time: 12:35 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5